Ulcerative colitis: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 200+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

No stopped trial with a stated reason in this view.

Trials whose registry record says individual participant data (IPD) will be shared.

• A Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Afimkibart (RO7790121) in Children With Moderately to Severely Active Ulcerative Colitis

  NCT07158242· Hoffmann-La Roche· Source

• A Sub Study to Investigate the Safety and Tolerability of Aletekitug in Participants With Moderate To Severe Ulcerative Colitis

  NCT07747480· GlaxoSmithKline· Source

• An Adaptive, Dose-Ranging, Phase 2 Study of Eltrekibart Given Alone or in Combination with Mirikizumab for the Treatment of Adult Patients with Moderately to Severely Active Ulcerative Colitis

  2023-507853-13-00· Eli Lilly & Co.· Source

• A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT05528510· Janssen Research & Development, LLC· Source

• LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis

  NCT07415044· Eli Lilly and Company· Source

• Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

  NCT06937086· Eli Lilly and Company· Source

• A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease

  NCT07483073· Eli Lilly and Company· Source

• A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT04033445· Janssen Research & Development, LLC· Source

• A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT05242484· Janssen Research & Development, LLC· Source

• LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:

  NCT07186101· Eli Lilly and Company· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 25
• Organoids 15
• Mendelian Randomization Analysis 48
• Gene Expression Profiling 76
• Sequence Analysis, RNA 5
• Whole Genome Sequencing 1
• Exome Sequencing 5
• Proteomics 29
• Metabolomics 48
• Mass Spectrometry 5
• Flow Cytometry 8
• Immunohistochemistry 18
• Magnetic Resonance Imaging 10
• Machine Learning 43
• Deep Learning 11
• Cohort Studies 89
• Genome-Wide Association Study 56

• Distinct intestinal eosinophil subsets in ulcerative colitis and their modulation by advanced inflammatory bowel disease therapies.

  J Crohns Colitis, Sept 2026

• Establishing a flow cytometry-based tissue receptor occupancy assay for an anti-oncostatin M receptor beta subunit therapeutic candidate in inflammatory bowel disease.

  Cytometry B Clin Cytom, Mar 2026

• Filgotinib treatment modulates frequency and gene expression of circulating immune cell subsets in ulcerative colitis.

  J Crohns Colitis, Mar 2026

• Berberine inhibits dendritic cells differentiation in DSS-induced colitis by promoting Bacteroides fragilis.

  Int Immunopharmacol, Nov 2021

• Dysregulated circulating dendritic cell function in ulcerative colitis is partially restored by probiotic strain Lactobacillus casei Shirota.

  Mediators Inflamm, Jul 2013

• Treatment of mice with dextran sulfate sodium-induced colitis with human interleukin 10 secreted by transformed Bifidobacterium longum.

  Mol Pharm, Feb 2011

• Resveratrol suppresses colitis and colon cancer associated with colitis.

  Cancer Prev Res (Phila), Mar 2010

• Probiotic Lactobacillus-induced improvement in murine chronic inflammatory bowel disease is associated with the down-regulation of pro-inflammatory cytokines in lamina propria mononuclear cells.

  Clin Exp Immunol, Jun 2005

See which targets of this disease your abstract mentions, and go to the people working on them.